Overview

Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.

Status:
Active, not recruiting

Trial end date:
2022-09-02

Target enrollment:

Participant gender:

Summary

This is a 20-week open-label study to evaluate the safety and efficacy of full-spectrum medicinal cannabis plant extract < 0.08% THC (FEN164) in children with Autism Spectrum Disorder.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Fenix Innovation Group

Collaborators:

Monash Health
Neurotech International